The new high-functionality excipient (HFE) CombiLac® is a lactose-based, co-processed excipient, specifically designed to ease oral solid dosage form development and manufacture in direct compression (DC).
CombiLac®, an innovative, co-processed HFE consists of the spray-dried, ternary admixture of alpha-lactose monohydrate, MCC and starch, each conforming with Ph. Eur., USP-NF, and JP compendial requirements. A well-defined manufacturing process generates porous, spherical particles with a highly integrated structure, inseparable by physical means.
CombiLac® shows improved compaction properties compared to an equivalent blend of individual ingredients, providing robust tablets with minimal friability. Rapid, hardness-independent tablet disintegration for effective API release is achieved easily, in addition to excellent powder flow characteristics necessary to enhance solid dosage form weight uniformity and throughput in tablet production.
CombiLac® is designed for DC applications but may be also used in other formulation development approaches such as dry granulation. In production, release testing is reduced due to its ternary composition. HFE CombiLac® compliments the differentiated functionality of Meggle’s comprehensive platform of co-processed excipients.
If robust, time saving development of frequently used formulation ingredients is a top priority, ready-to-use CombiLac® is the best choice.
About MEGGLE:
MEGGLE AG, with its headquarters in the Bavarian city of Wasserburg (Germany), serves as a holding company for various business activities in the dairy industry and whey processing. MEGGLE has a proud history of more than 125 years in the dairy market.
The business group Excipients & Technology produces pharmaceutical excipients for direct compression, granulation, capsules, sachets, powder blends and dry powder inhalers. With its broad product portfolio, intelligent innovations and exceptional product quality, Meggle took a leading role in the global business of pharmaceutical excipients.
For more information please visit www.meggle-pharma.com
MEGGLE Gruppe Wasserburg
BG Excipients & Technology
Megglestraße 6 –12
83512 Wasserburg
Germany
Dr. Egmont Pfeifer
Phone +49 8071 73 476
Fax +49 8071 73 320
[email protected]
www.meggle-pharma.com